Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo). Based on available data, the serious risks including the increase in thromboembolic
Similar Posts
www.peacefulmeds.com – 703470 – 05/05/2025
Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the InternetIpca Laboratories Limited – 12/5/2025
Ipca Laboratories Limited – 12/5/2025. Country: India. Record Type: 483List of Determinations Including Written Request
In accordance with section 505A(e)(1) of the Act, as amended by FDAAA (Pub. L. No. 110-85), the following list identifies those approved drugs for which a pediatric exclusivity determination was made, on or after September 27, 2007.Bertrand P. Cole, D.O. – 723495 – 02/02/2026
Clinical InvestigatorOffice of New Drugs Custom Medical Queries (OCMQs)
Office of New Drugs Custom Medical Queries (OCMQs) are standardized groupings of similar adverse event terms intended to assist with the identification of potential safety issues during review of adverse event data.DeVere Manufacturing Inc. – 715846 – 11/12/2025
CGMP/Finished Pharmaceuticals/Adulterated